Q3 2021 13F Holders as of 9/30/2021
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
105M
-
Number of holders
-
153
-
Total 13F shares, excl. options
-
54.8M
-
Shares change
-
+751K
-
Total reported value, excl. options
-
$1.53B
-
Value change
-
+$20.2M
-
Put/Call ratio
-
2.29
-
Number of buys
-
68
-
Number of sells
-
-59
-
Price
-
$27.86
Significant Holders of Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share (RVNC) as of Q3 2021
181 filings reported holding RVNC - Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share as of Q3 2021.
Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share (RVNC) has 153 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 54.8M shares
of 105M outstanding shares and own 52.38% of the company stock.
Largest 10 shareholders include BlackRock Inc. (5.37M shares), JPMORGAN CHASE & CO (5.08M shares), VANGUARD GROUP INC (3.58M shares), ALLIANCEBERNSTEIN L.P. (3.28M shares), Palo Alto Investors LP (3.2M shares), Capital World Investors (2.97M shares), ArrowMark Colorado Holdings LLC (2.81M shares), FMR LLC (2.69M shares), JENNISON ASSOCIATES LLC (2.09M shares), and FRANKLIN RESOURCES INC (1.82M shares).
This table shows the top 153 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.